Methods: Clinical (neurological, endocrine, and general) and hormonal evaluations were performed using a standardized protocol including determination of FT4, TSH, PRL, IGF1, testosterone/E2, FSH and LH. Corticotrope and somatotrope axes were evaluated using glucagon-, insulin tolerance- or GHRH-arginine tests.

Conclusion: Our data in the prospective cohort confirm that pituitary dysfunction after TBI may evolve over time and requires multiple evaluations. Prospective interventions studies are needed to evaluate the benefits of hormonal supplementation in these patients.